Abstract:
RNA biology has revolutionized cancer understanding and treatment, especially
in endocrine-related malignancies. This editorial highlights RNA's crucial role in
cancer progression, emphasizing its influence on tumor heterogeneity and
behavior. Processes like alternative splicing and noncoding RNA regulation
shape cancer biology, with microRNAs, long noncoding RNAs, and circular
RNAs orchestrating gene expression dynamics. Aberrant RNA signatures hold
promise as diagnostic and prognostic biomarkers in endocrine-related cancers.
Recent findings, such as aberrant PI3Kd splice isoforms and epithelialmesenchymal transition-related lncRNA signatures, unveil potential therapeutic
targets for personalized treatments. Insights into m6A-associated lncRNA
prognostic models and the function of lncRNA LINC00659 in gastric cancer
represents ongoing research in this field. As understanding of RNA's role in
cancer expands, personalized therapies offer transformative potential in
managing endocrine-related malignancies. This signifies a significant stride
towards precision oncology, fostering innovation for more effective cancer care.
